Raymond James Financial began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD - Free Report) in a research report report published on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $62.00 price objective on the stock.
Other analysts also recently issued reports about the stock. Cantor Fitzgerald started coverage on shares of Tvardi Therapeutics in a research note on Friday, July 11th. They set an "overweight" rating and a $52.00 target price on the stock. Oppenheimer started coverage on Tvardi Therapeutics in a research note on Wednesday, May 21st. They set an "outperform" rating and a $65.00 target price on the stock. Wall Street Zen raised shares of Tvardi Therapeutics to a "hold" rating in a research report on Saturday, May 24th. Finally, Piper Sandler began coverage on shares of Tvardi Therapeutics in a report on Thursday, June 12th. They set an "overweight" rating and a $78.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Tvardi Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $64.25.
Read Our Latest Stock Report on Tvardi Therapeutics
Tvardi Therapeutics Stock Performance
NASDAQ TVRD traded up $1.32 on Monday, hitting $24.06. 21,474 shares of the company were exchanged, compared to its average volume of 34,758. Tvardi Therapeutics has a twelve month low of $8.13 and a twelve month high of $34.31.
About Tvardi Therapeutics
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Articles
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
